AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

ClearOne, Inc.

$4.41 -$0.87 (-16.48%)
NASDAQ · 15 Sep 2026 20:00 UTC
Previous Close
$4.58
Day Range
$4.41$4.65
Year Range
$2.71$16.5
Market Cap
11.8M
AVG Volume
3.18M
Trailing/Forward PE
-0.41/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
05M10M15M20M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q20
26 Q11.92M
25 Q44.23M
25 Q37.18M
25 Q29.69M
25 Q110.08M
24 Q411.39M
24 Q312.58M
24 Q214.97M
24 Q118.15M
Net Income (USD) · TTM
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-20.08M
26 Q1-23.74M
25 Q4-26.08M
25 Q3-23.34M
25 Q2-11.67M
25 Q1-9.92M
24 Q4-8.98M
24 Q3-4.14M
24 Q2-3.43M
24 Q1-1.63M
Operating Income (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-3.76M
26 Q1-7.4M
25 Q4-9.39M
25 Q3-10.28M
25 Q2-11.61M
25 Q1-9.98M
24 Q4-9.21M
24 Q3-8.93M
24 Q2-8.23M
24 Q1-6.66M
EBITDA (USD) · TTM
-15M-10M-5M05M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-3.55M
26 Q1-7M
25 Q4-8.95M
25 Q3-9.61M
25 Q2-10.77M
25 Q1-9M
24 Q4-8.01M
24 Q3-2.77M
24 Q2-1.72M
24 Q1281K
Cash Flows (USD) · TTM
-10M-7.5M-5M-2.5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-6.13M
26 Q1-6.23M
25 Q4-6.27M
25 Q3-4.92M
25 Q2-6.04M
25 Q1-8.13M
24 Q4-6.31M
24 Q3-1.25M
24 Q2-1.2M
24 Q1-5.68M
EPS (USD) · TTM
-2-1.5-1-0.5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-1.9
26 Q1-1.89
25 Q4-1.8
25 Q3-1.53
25 Q2-0.62
25 Q1-0.41
24 Q4-0.38
24 Q3-0.18
24 Q2-0.15
24 Q1-0.07
Expenses (USD) · TTM
-5M05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q26.2M
26 Q19.65M
25 Q411.86M
25 Q311.88M
25 Q213.08M
25 Q111.72M
24 Q412.04M
24 Q312.41M
24 Q212.74M
24 Q113.27M
Shares Outstanding (USD) · TTM
-500K0500K1M1.5MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CLRO Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2965K
26 Q1973K
25 Q4928K
25 Q3916K
25 Q2-83K
25 Q1-91K
24 Q4-94K
24 Q3-98K
24 Q2-110K
24 Q1-112K
Dividends (USD)
02468May 16Aug 16Nov 16Feb 17May 17Aug 17Nov 17Mar 18Jun 23Apr 24
CLRO Dividends (USD) by quarter
PeriodDividends (USD)
Apr 247.5
Jun 231
Mar 180.07
Nov 170.07
Aug 170.07
May 170.07
Feb 170.05
Nov 160.05
Aug 160.05
May 160.05
Employee Count
0501001502002015201620172018201920202021202220232024
CLRO Employee Count by quarter
PeriodEmployee Count
202480
202382
202282
2021107
2020126
2019127
2018130
20172
2016151
2015165
PE Ratio
0100020003000med 32.57Jul 21Nov 21Feb 22May 23Sep 23Dec 23Mar 24
CLRO PE Ratio by quarter
PeriodPE Ratio
Mar 2431.58
Mar 2431.06
Mar 2429.68
Mar 2415.8
Mar 2416.13
Feb 2416.51
Feb 2417.08
Feb 2417.43
Feb 2417.95
Jan 2416.91
Jan 2417.43
Jan 2417.43
Jan 2417.18
Dec 2318.64
Dec 2314.5
Dec 2314.32
Dec 2313.98
Dec 2314.19
Nov 2313.97
Nov 2312.34
Nov 2311.62
Nov 2311.47
Oct 2311.21
Oct 2311.68
Oct 2312.42
Oct 2312.79
Sep 2313.04
Sep 2313.47
Sep 2313.91
Sep 2313.94
Sep 2315.35
Aug 2314.69
Aug 2313.91
Aug 2313.11
Aug 2313.39
Jul 2312.83
Jul 2312.91
Jul 2313.01
Jul 2312.44
Jun 2313.72
Jun 2314.73
Jun 2316.07
Jun 2315.23
Jun 2319.05
May 2336.61
May 2342.24
May 2333.56
May 2321.32
Apr 2322.37
Apr 2321.15
Apr 2322.9
Apr 2323.25
Mar 2326.39
Apr 221930.94
Apr 221993.9
Apr 221825.99
Mar 221888.96
Mar 221832.99
Mar 221631.5
Mar 221791.01
Feb 221867.97
Feb 222002.3
Feb 222076.46
Feb 222119.83
Jan 221972.91
Jan 222035.88
Jan 222476.64
Jan 222896.4
Dec 212707.51
Dec 212791.46
Dec 212644.54
Dec 212938.38
Dec 212770.47
Nov 212959.37
Nov 212833.44
Nov 212770.47
Nov 21403.11
Oct 21424.61
Oct 21472.98
Oct 21556.29
Oct 21588.54
Oct 21628.85
Sep 21653.03
Sep 21644.97
Sep 21730.97
Sep 21701.41
Aug 21698.72
Aug 21709.47
Aug 21687.97
Aug 211036.85
Jul 211127.87
Jul 211092.25
Jul 21981.44
Jul 211060.59
Jul 21930
Jun 211040.81
Jun 21926.04
Jun 21989.36
Jun 21969.57
May 21945.83
Free Cash Flow Yield
-150%-100%-50%0%med -42.84%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CLRO Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-50.04%
Sep 26-45.93%
Sep 26-45.03%
Aug 26-42.76%
Aug 26-42.92%
Aug 26-43.91%
Aug 26-25.69%
Jul 26-64.05%
Jul 26-48.93%
Jul 26-35.8%
Jul 26-31.15%
Jul 26-40.33%
Jun 26-83.22%
Jun 26-77.54%
Jun 26-70.25%
Jun 26-82.69%
May 26-80.4%
May 26-79.43%
May 26-84.02%
May 26-112.06%
May 26-101.2%
Apr 26-110.32%
Apr 26-111.01%
Apr 26-112.06%
Apr 26-112.41%
Mar 26-74.63%
Mar 26-64.6%
Mar 26-64.3%
Mar 26-62.33%
Feb 26-58.35%
Feb 26-53.91%
Feb 26-44.1%
Feb 26-40.22%
Jan 26-43.83%
Jan 26-41.34%
Jan 26-41.22%
Jan 26-50.37%
Jan 26-53.71%
Dec 25-53.2%
Dec 25-52.81%
Dec 25-53.51%
Dec 25-53.61%
Nov 25-53.81%
Nov 25-66.1%
Nov 25-51.94%
Nov 25-69.97%
Oct 25-62.23%
Oct 25-68.87%
Oct 25-69.97%
Oct 25-58.76%
Oct 25-61.03%
Sep 25-68.87%
Sep 25-64.65%
Sep 25-73.83%
Sep 25-70.97%
Aug 25-86.47%
Aug 25-83.57%
Aug 25-82.97%
Aug 25-7.13%
Aug 25-7.21%
Jul 25-5.71%
Jul 25-4.16%
Jul 25-3.06%
Jul 25-3.29%
Jun 25-5.95%
Jun 25-5.67%
Jun 25-5.72%
Jun 25-5.46%
May 25-6.56%
May 25-5.54%
May 25-4.25%
May 25-3.28%
May 25-3.37%
Apr 25-3.19%
Apr 25-3.54%
Apr 25-3.65%
Apr 25-3.8%
Mar 25-2.89%
Mar 25-0.55%
Mar 25-0.54%
Mar 25-0.47%
Feb 25-0.67%
Feb 25-0.66%
Feb 25-0.72%
Feb 25-0.67%
Jan 25-0.64%
Jan 25-0.59%
Jan 25-0.56%
Jan 25-0.42%
Jan 25-0.26%
Dec 24-0.57%
Dec 24-0.57%
Dec 24-0.63%
Dec 24-0.58%
Nov 24-0.68%
Nov 24-0.7%
Nov 24-0.68%
Nov 24-0.6%
Nov 24-0.58%
Oct 24-0.57%
Price to Sales
010203040med 9.76Nov 24Feb 25Jun 25Sep 25Jan 26Apr 26Aug 26
CLRO Price to Sales by quarter
PeriodPrice to Sales
Aug 2612.65
Jul 265.08
Jul 266.64
Jul 269.08
Jul 2610.44
Jul 268.06
Jun 263.91
Jun 264.19
Jun 264.63
Jun 263.93
May 264.04
May 264.09
May 263.87
May 261.32
May 261.47
Apr 261.34
Apr 261.34
Apr 261.32
Apr 261.32
Mar 260.92
Mar 261.06
Mar 261.06
Mar 261.1
Feb 261.17
Feb 261.27
Feb 261.55
Feb 261.7
Jan 261.56
Jan 261.66
Jan 261.66
Jan 261.36
Jan 261.27
Dec 251.29
Dec 251.3
Dec 251.28
Dec 251.28
Nov 251.27
Nov 251.04
Nov 251.32
Nov 250.89
Oct 251
Oct 250.91
Oct 250.89
Oct 251.06
Oct 251.02
Sep 250.91
Sep 250.96
Sep 250.84
Sep 250.88
Aug 250.72
Aug 250.75
Aug 250.75
Aug 2511.32
Aug 2511.2
Jul 2514.12
Jul 2519.38
Jul 2526.4
Jul 2524.56
Jun 2513.56
Jun 2514.24
Jun 2514.1
Jun 2514.78
May 2512.3
May 2514.56
May 2518.98
May 2516.92
May 2516.44
Apr 2517.36
Apr 2515.68
Apr 2515.17
Apr 2514.58
Mar 2519.15
Mar 2518.09
Mar 2518.34
Mar 2521.16
Feb 2514.78
Feb 2514.91
Feb 2513.83
Feb 2514.86
Jan 2515.49
Jan 2516.93
Jan 2517.56
Jan 2523.64
Jan 2537.43
Dec 2417.39
Dec 2417.5
Dec 2415.75
Dec 2417.14
Nov 2414.55
Nov 2414.15
Nov 2414.57
Nov 2413.35
Nov 2413.69
Oct 2413.93
Oct 2414.17
Oct 2414.04
Oct 2414.43
Sep 2414.65
Sep 2413.87
Sep 2413.88
EV/EBITDA
050010001500med 21.82Jul 17Oct 17Jun 23Sep 23Jan 24Apr 24Aug 24
CLRO EV/EBITDA by quarter
PeriodEV/EBITDA
Aug 24756.87
Aug 24790.13
Jul 24839.61
Jul 24825.11
Jul 24808.9
Jul 24806.34
Jun 24757.72
Jun 24834.49
Jun 24847.28
Jun 24823.4
May 24892.49
May 24895.05
May 241077.59
May 24174.97
May 24204.15
Apr 24176.21
Apr 24185.38
Apr 24193.47
Apr 24298.66
Mar 2421.44
Mar 2421.08
Mar 2420.11
Mar 2410.43
Mar 2410.66
Feb 2410.93
Feb 2411.33
Feb 2411.57
Feb 2411.93
Jan 2411.21
Jan 2411.57
Jan 2411.57
Jan 2411.39
Dec 2312.41
Dec 239.52
Dec 239.4
Dec 239.16
Dec 239.31
Nov 239.16
Nov 238.02
Nov 237.52
Nov 237.22
Oct 237.04
Oct 237.36
Oct 237.87
Oct 238.12
Sep 238.29
Sep 238.59
Sep 238.89
Sep 238.91
Sep 239.88
Aug 239.42
Aug 238.89
Aug 238.34
Aug 237.31
Jul 236.94
Jul 236.99
Jul 237.06
Jul 236.67
Jun 237.54
Jun 238.23
Jun 239.13
Jun 238.56
Jun 2311.15
May 2323.07
May 2326.89
May 2322.2
May 2314.15
Apr 2314.84
Apr 2314.03
Apr 2315.18
Apr 2315.41
Mar 2317.48
Nov 171149.42
Nov 171222.27
Oct 171253.49
Oct 171288.18
Oct 171279.51
Oct 171288.18
Sep 171279.51
Sep 171340.22
Sep 171314.2
Sep 171279.51
Sep 171296.85
Aug 171322.87
Aug 171322.87
Aug 171296.85
Aug 17394.68
Jul 17407.09
Jul 17396.75
Jul 17394.68
Jul 17396.75
Jun 17385.58
Jun 17384.34
Jun 17394.68
Jun 17392.61
Jun 17407.09
May 17411.23
May 17405.02
May 17411.23
May 17244.87
Price/Operating Cashflow
0200040006000med 13.65Jun 17Oct 17Jan 21Jun 23Oct 23Jan 24May 24
CLRO Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
May 245.97
May 246.91
Apr 246.01
Apr 246.31
Apr 246.57
Apr 249.93
Mar 2413.42
Mar 2413.2
Mar 2412.61
Mar 246.71
Mar 246.85
Feb 247.01
Feb 247.26
Feb 247.4
Feb 247.62
Jan 247.18
Jan 247.4
Jan 247.4
Jan 247.3
Dec 237.92
Dec 236.16
Dec 236.08
Dec 235.94
Dec 236.03
Nov 235.93
Nov 235.24
Nov 234.94
Nov 234.67
Oct 234.56
Oct 234.75
Oct 235.05
Oct 235.2
Sep 235.31
Sep 235.48
Sep 235.66
Sep 235.67
Sep 236.25
Aug 235.98
Aug 235.66
Aug 235.33
Aug 235.08
Jul 234.87
Jul 234.9
Jul 234.93
Jul 234.72
Jun 235.2
Jun 235.59
Jun 236.1
Jun 235.78
Jun 237.23
May 2313.89
May 2316.02
Mar 21529.07
Mar 21632.34
Mar 21641.88
Mar 21544.96
Feb 21511.6
Feb 21571.97
Feb 21567.2
Feb 21490.94
Jan 21449.63
Jan 21449.63
Jan 21374.96
Jan 21392.43
Dec 20360.66
Dec 20394.02
Dec 20373.37
Dec 20440.1
Dec 20370.19
Nov 20421.03
Nov 20317.76
Nov 175076.77
Nov 175395.02
Oct 175531.41
Oct 175682.95
Oct 175645.07
Oct 175682.95
Sep 175645.07
Sep 175910.27
Sep 175796.61
Sep 175645.07
Sep 175720.84
Aug 175834.5
Aug 175834.5
Aug 175720.84
Aug 17289.44
Jul 17298.44
Jul 17290.94
Jul 17289.44
Jul 17290.94
Jun 17282.84
Jun 17281.94
Jun 17289.44
Jun 17287.94
Jun 17298.44
May 17301.44
May 17296.94
May 17301.44
May 17178.98
Apr 17178.13
Price to Book
0204060med 7.93Oct 24Jan 25May 25Aug 25Nov 25Mar 26Aug 26
CLRO Price to Book by quarter
PeriodPrice to Book
Aug 2645.57
Jul 2618.28
Jul 2623.93
Jul 2632.71
Jul 2637.59
Jul 2629.04
Jun 2614.07
Jun 2615.1
Jun 2616.67
Jun 2614.16
May 2614.56
May 2614.74
May 2613.94
Mar 261.9
Mar 262.2
Mar 262.21
Mar 262.28
Feb 262.44
Feb 262.64
Feb 263.22
Feb 263.53
Jan 263.24
Jan 263.44
Jan 263.45
Jan 262.82
Jan 262.65
Dec 252.67
Dec 252.69
Dec 252.66
Dec 252.65
Nov 252.64
Nov 252.15
Nov 252.74
Nov 250.58
Oct 250.65
Oct 250.59
Oct 250.58
Oct 250.69
Oct 250.66
Sep 250.59
Sep 250.63
Sep 250.55
Sep 250.57
Aug 250.47
Aug 250.48
Aug 250.49
Aug 255.85
Aug 255.78
Jul 257.29
Jul 2510.01
Jul 2513.63
Jul 2512.68
Jun 257
Jun 257.36
Jun 257.28
Jun 257.63
May 256.35
May 257.52
May 259.8
May 259.03
May 258.77
Apr 259.27
Apr 258.37
Apr 258.1
Apr 257.78
Mar 2510.22
Mar 259.69
Mar 259.82
Mar 2511.33
Feb 257.91
Feb 257.99
Feb 257.4
Feb 257.96
Jan 258.29
Jan 259.07
Jan 259.4
Jan 2512.66
Jan 2520.04
Dec 249.31
Dec 249.37
Dec 248.43
Dec 249.18
Nov 247.79
Nov 247.58
Nov 247.8
Nov 247.82
Nov 248.02
Oct 248.16
Oct 248.3
Oct 248.23
Oct 248.45
Sep 248.58
Sep 248.12
Sep 248.13
Sep 247.73
Aug 248.2
Aug 248.2
Aug 248.44
Aug 248.24
Aug 248.57
ClearOne, Inc.
CLRO
Stockpicker

Video analysis: CLRO

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CLRO

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ClearOne, Inc. (NYSE: CLRO)

prnewswire.com · 9 Jul 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ClearOne, Inc. (NYSE: CLRO)

NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating ClearOne, Inc. (NYSE: CLRO ) related to its merger with Cortigent, Inc. Upon completion of the proposed transaction, ClearOne shareholders will own approximately 12.7% to 14.4% of the outstanding equity in the combined company.

CLRO Stock Alert: Halper Sadeh LLC is Investigating Whether ClearOne, Inc. is Obtaining a Fair Price for its Shareholders

businesswire.com · 6 Jul 2026

CLRO Stock Alert: Halper Sadeh LLC is Investigating Whether ClearOne, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ClearOne, Inc. (NYSE: CLRO) and Cortigent, Inc. Upon closing of the Proposed Transaction, ClearOne shareholders will own 12.7% to 14.4% of the outstanding equity in the combined company.Halper Sadeh encourages ClearOne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or z.

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

globenewswire.com · 2 Jul 2026

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company's name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and "CRGT" Cortigent is a leading developer of brain computer interface ("BCI") devices based on precision neurostimulation technology ALAMEDA, Calif.

ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

businesswire.com · 2 Jul 2026

ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned subsidiary (“MergerSub”), Vivani Medical, Inc. (Nasdaq: VANI; “Vivani”), and Cortigent, Inc. (“Cortigent”), a wholly-owned subsidiary of Vivani, pursuant to which Cortigent will become a wholly-owned subsidiary of ClearOne (the “Transaction”) upon consummation. In connection with the Transaction, C.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.